title: [Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak].
abstract: Shiga toxin-associated hemolytic uremic syndrome (HUS) is an entity of thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, central nervous symptoms, and renal insufficiency. In May 2011, an outbreak of enterohemorrhagic Escherichia coli (EHEC; O104:H4) occurred in Northern Germany. By the end of July 2011, the outbreak was over but nearly 4000 patients had an EHEC infection, 855 cases of hemolytic-uraemic syndrome were reported to the Robert Koch Institute, and there were 35 (4.1%) deaths. Shiga toxin-induced HUS is a rare disease and no controlled clinical trials on therapeutic options are available. First analyses of this outbreak suggest that therapeutic plasma exchange, which was used in the majority of patients, had no benefit and might even be harmful. The role of eculizumab, a monoclonal antibody which inhibits the complement system, is being examined in a multicenter study: the results have not been published yet. Promising is the use of some antibiotics. This would change a paradigm that antibiotics should be avoided. Ongoing and future analyses of the epidemic should be awaited before a final recommendation regarding the different treatment strategies can be made.
authors.affiliation: Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, Hannover, Germany. menne.jan@mh-hannover.de
authors.forename: J
authors.initials: J
authors.lastname: Menne
authors.forename: J T
authors.initials: JT
authors.lastname: Kielstein
authors.forename: U
authors.initials: U
authors.lastname: Wenzel
authors.forename: R A K
authors.initials: RA
authors.lastname: Stahl
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome; D004196:Disease Outbreaks / Q000517:prevention & control* / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D007722:Health Knowledge, Attitudes, Practice; D006463:Hemolytic-Uremic Syndrome / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D010951:Plasma Exchange / Q000401:mortality*; D012307:Risk Factors; D054323:Shiga-Toxigenic Escherichia coli; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents